Holen Sie sich die Stockscreener-App
270.78
1.50%
-4.13
Handel nachbörslich:
270.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$274.91
Offen:
$273.09
24-Stunden-Volumen:
1.30M
Relative Volume:
0.78
Marktkapitalisierung:
$52.68B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
20.77
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
+1.73%
1M Leistung:
-12.14%
6M Leistung:
-26.52%
1J Leistung:
-7.38%
1-Tages-Spanne:
$270.23
$274.92
1-Wochen-Bereich:
$261.90
$277.39
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
270.78 | 53.49B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
754.40 | 92.09B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
200.37 | 47.00B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
73.90 | 8.45B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.60 | 1.31B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Cencora hits 52-week low after guidance cut - MSN
Cencora, Inc. (COR) Stock Analysis: Healthcare Giant With A 29.80% Upside Potential - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): new leadership move as former CEO returns as chair amid healthcar - AD HOC NEWS
Cencora Inc (COR) Stock Up 3.6% and Still Undervalued -- GF Scor - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Investors to Connect - ACCESS Newswire
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora raises earnings outlook on share repurchases - Seeking Alpha
Cencora Inc. stock (US15135B1017): guidance tweak and extra $2 billion buyback attract fresh attenti - AD HOC NEWS
Cencora: Board of Directors Authorized New Shr Repurchase Program to Purchase Up to Additional $2.0B of Stk >COR - Moomoo
Cencora Raises Fiscal 2026 EPS Outlook, Authorizes $2 Billion Share Buyback - Moomoo
Cencora revises forecast for 2026, approves $2 billion share buyback - marketscreener.com
$2 billion stock buyback: Cencora lifts 2026 earnings forecast - Stock Titan
Cencora Announces Updated Fiscal Year 2026 Financial Outlook - marketscreener.com
Cencora, Inc. announces an Equity Buyback for $2,000 million worth of its shares. - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc.COR - PR Newswire
Cencora stock (US15135B1017): transformation story after name change and solid earnings - AD HOC NEWS
COR's MWI Animal Health to merge with Covetrus in $3.5 billion deal - MSN
Cencora, Inc. authorizes a Buyback Plan. - marketscreener.com
Deals tracker: Medtronic to acquire SPR Therapeutics for $650M - Modern Healthcare
Cencora stock (US15135B1017): Earnings miss and legal probe weigh on shares - AD HOC NEWS
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Cencora stock (US15135B1017): Q2 miss, legal probe and what matters now for investors - AD HOC NEWS
Cencora stock (US15135B1017): dividend track record and legal investigation in focus - AD HOC NEWS
Investors can join fraud probe against Cencora after Q2 miss and revenue drop claims. - Pluang
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating - Insider Monkey
Cencora stock (US15135B1017): revenue miss, guidance tweak and share price pressure in focus - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Stockholders to Connect - ACCESS Newswire
Cencora Inc. stock underperforms Wednesday when compared to competitors - MSN
Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative? - simplywall.st
The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call - Yahoo Finance
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? - MSN
Is It Time To Revisit Cencora (COR) After The Recent Share Price Slump? - simplywall.st
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR - Business Wire
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora stock (US15135B1017): pharma distributor reshapes portfolio after latest earnings - AD HOC NEWS
Wells Fargo Maintains Overweight Rating on Cencora (COR) - Insider Monkey
Cencora, Inc. Common Stock (NY: COR - FinancialContent
Cencora faces securities fraud probe after missing revenue targets and stock plunge. - Pluang
Cencora, Inc.: - marketscreener.com
Cencora Inc. stock (US15135B1017): dividend date and legal probe in focus for investors - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? - TradingView
ETFs Investing in Cencora, Inc. Stocks - TradingView
Are Wall Street Analysts Bullish on Cencora Stock? - Yahoo Finance
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):